Skip to main content

Table 5 Associations between CYP17 genotypes and breast cancer risk stratified by selected characteristics

From: CYP17, GSTP1, PON1 and GLO1gene polymorphisms as risk factors for breast cancer: an Italian case-control study

 

Premenopausal

Postmenopausal

 

A1A1

A1/A2 and A2A2

A1A1

A1/A2 and A2A2

 

Case/Control

ORa (95% CI)

Case/Control

ORa (95% CI)

Case/Control

ORa (95% CI)

Case/Control

ORa (95% CI)

Age at menarche

        

< 13 yr

25/11

1.0

23/26

1.0

19/25

1.0

32/25

1.0

≥ 13 yr

64/89

0.28 (0.10–0.71)

75/104

0.77 (0.39–1.53)

119/103

1.31 (0.63–2.72)

190/161

0.84 (0.44–1.61)

Postmenopausal use of estrogen

        

Never

    

100/89

1.0

154/119

1.0

Ever

    

39/40

1.15 (0.63–2.12)

67/66

0.86 (0.52–1.41)

Use of oral contraceptives

        

Never

28/27

1.0

33/32

1.0

106/86

1.0

192/130

1.0

Ever

64/74

1.01 (0.45–2.27)

62/97

0.55 (0.29–1.03)

32/41

0.83 (0.41–1.74)

30/57

0.52 (0.29–0.98)

Parity

        

Nulliparous

21/9

1.0

14/15

1.0

30/16

1.0

51/25

1.0

Parous

68/91

0.26 (0.10–0.60)

84/115

0.77 (0.32–1.94)

109/109

0.53 (0.25–1.08)

170/164

0.97 (0.36–1.17)

Age at FFTP for parous women

        

≤ 25 yr

48/47

1.0

51/66

1.0

65/64

1.0

105/119

1.0

> 25 yr

22/35

0.83 (0.45–1.55)

33/43

1.34 (0.61–2.89)

43/42

0.92 (0.53–1.65)

64/63

0.59 (0.28–1.47)

BMI

        

≤ 25,4

63/67

1.0

51/76

1.0

53/51

1.0

76/77

1.0

> 25,4

28/35

0.60 (0.27–1.34)

45/52

1.05 (0.57–1.93)

86/76

1.43 (0.75–2.72)

145/110

1.64 (0.97–2.78)

WHR

        

< 0,91

41/58

1.0

42/72

1.0

47/58

1.0

86/82

1.0

≥ 0,91

47/40

1.61 (0.83–3.17)

57/60

1.52 (0.85–2.75)

91/68

1.68 (0.95–2.99)

136/106

1.12 (0.70–1.97)

  1. aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen.